Replies to post #187215 on Avid Bioservices Inc (CDMO)

[biopharm]

Knock Knock Mr. Hutschi....we're now under 30 days away from ELCC and noticed Peregrine KOL Scott Antonia part of some PD-L1 MEDI4736 trial and looking up MEDI4736 that is a very real possibility of a current collaboration with Peregrine

PPHM/Dr. Carbone is also at the ELCC 2015 - 15-18 April 2015 in Geneva

2Q 2015 - is that the right time for you CP smile

The evolving role of immunotherapy for lung cancer
http://www.esmo.org/Conferences/ELCC-2015-Lung-Cancer/Programme

IASLC and ESMO are pleased to announce that the European Lung Cancer Conference (ELCC), will become an annual meeting as of 2015.

ELCC will enlarge cooperation with the most important societies representing thoracic oncology specialists, forming a truly multidisciplinary team and reinforcing the science, education and practice of lung cancer across Europe and beyond.

We invite you to save the date for the 5th European Lung Cancer Conference, 15-18 April in Geneva, Switzerland.

ELCC Co-chairs:

Dominique Grunenwald, Paris, France
Johan Vansteenkiste, Leuven, Belgium

-------------------------------------------------------


Main themes for ELCC 2015

Evolving role of surgery in metastatic disease
Refining radiotherapy for lung cancer
Expanding role of biomarkers for NSCLC
Immunotherapy in our treatment paradigm
Evolving ablative strategies in oncogene driven tumours
Groundbreaking approaches in SCLC and mesothelioma

This multidisciplinary thoracic oncology conference addresses the scientific and educational needs of key specialists and trainees: medical and radiation oncologists, thoracic surgeons, pathologists, pulmonologists, radiologists, research physicians and allied health professionals. Topics will include:


Molecular testing in advanced NSCLC: clinical practice, clinical trials, emerging biomarkers

Immunotherapy in NSCLC: new findings and how to select patients for this approach

Role of local therapies in oligoprogressive oncogenic-driven lung cancer

Surgical and radiotherapeutic approaches to oligometastatic disease

Advanced NSCLC without driver mutations: treatment approaches

Small cell lung cancer: the evolving role of radiotherapy

Mesothelioma: standards and controversies

Specialty sessions for profound discussion of discipline specific controversies

http://www.esmo.org/Conferences/ELCC-2015-Lung-Cancer

-------------------------------------------------------

.... we have Dr. David Carbone speaking re: "Clinical Trial Designs and Perspectives"

.... we have Dr. Scott J. Antonia re: as part of the PD-L1 (MEDI7436)and just to note and give example: MEDI4736 does say it wants to be part of "combination therapies" and we all know its all about combination these days and Scott Antonia just may have super leverage to make MEDI4736 a collaborator with Bavi combinations or would MEDI4736 be part of the current collaborations already?

http://www.immunotherapyofcancer.org/content/2/S3/P179/comments

..... also seen David Carbone again, this time as "Chair.." of "Can adaptive design help to proceed in clinical trials in lung cancer?" and this session is more of a debate it looks like, as each side gives their reasons:

5 reasons pro = B. Besse, FR

5 reasons contra = M. Buyse, BE

http://www.esmo.org/content/download/39036/760655/file/ELCC-2015-Final-Programme.pdf

--------------------------------------------------------